【摘要】：目的表皮生長因子受體絡(luò)氨酸激酶抑制劑在非小細胞肺癌個性化治療中的應(yīng)用受到廣泛關(guān)注,但目前鹽酸�？颂婺崧�(lián)合放療及微波熱療治療局部晚期非小細胞肺癌的療效尚未見報道。本研究旨在對比分析鹽酸�？颂婺崧�(lián)合放療和微波熱療與單純放療聯(lián)合微波熱療治療晚期非小細胞肺癌療效及毒副作用。方法選取2013-04-01-2015-03-31青島市膠州中心醫(yī)院放療科收治的36例局部晚期非小細胞肺癌患者作為研究對象。年齡46~69歲,中位年齡56歲。根據(jù)EGFR基因突變情況分組,試驗組17例,男9例,女8例;對照組19例,男10例,女9例。試驗組患者行胸部三維適形放療DT:50~60Gy,放療期間聯(lián)合微波熱療及鹽酸埃克替尼(凱美納),125mg,口服,3次/d。對照組患者進行單純放療聯(lián)合微波熱療。比較兩組患者近期療效及毒副作用。治療結(jié)束后第1、3、6和12個月評價療效。結(jié)果第1個月試驗組和對照組PR分別為58.8%和52.6%(χ~2=0.139 3,P=0.709 0),SD分別為41.2%和47.4%(χ~2=0.139 3,P=0.709 0)。第3個月,試驗組和對照組PR分別為64.7%和36.8%,(χ~2=3.950 6,P=0.046 9),SD分別為35.3%和26.3%(χ~2=2.184 4,P=0.044 3),PD分別為0和26.3%(χ~2=5.195 2,P=0.022 6),DCR分別為100.0%和63.2%(χ~2=7.775 0,P=0.053),試驗組與對照組相比差異均有統(tǒng)計學意義。12個月時試驗組部分緩解率(PR)為58.8%,疾病穩(wěn)定率(SD)為41.2%,無疾病進展(PD);對照組PR為31.6%,SD為47.4%,PD為21.0%。試驗組從治療結(jié)束到癥狀緩解的時間明顯少于對照組,P=0.014。試驗組中放射性肺炎的發(fā)生率為17.6%,對照組為31.6%,對照組放射性肺炎的發(fā)生于率高于試驗組,P=0.034。結(jié)論鹽酸�？颂婺崧�(lián)合放療及微波熱療治療局部晚期非小細胞肺癌近期療效優(yōu)于行單純放療聯(lián)合微波熱療的患者,毒副作用輕。
[Abstract]:Objective the application of epidermal growth factor receptor collaterine kinase inhibitor in individualized treatment of non-small cell lung cancer (NSCLC) has been widely concerned, but the efficacy of facetinib hydrochloric acid combined with radiotherapy and microwave hypertherapy in the treatment of locally advanced non-small cell lung cancer has not been reported. The purpose of this study was to compare the efficacy and side effects of etinib hydrochloric acid combined with radiotherapy and microwave hypertherapy combined with radiotherapy alone in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 36 patients with locally advanced non-small cell lung cancer (NSCLC) treated in radiotherapy Department of Jiaozhou Central Hospital of Qingdao City were selected from 2013 / 04 / 01 / 2015 / 03 / 31. The age was 46 times 69 years old, and the median age was 56 years old. According to the mutation of EGFR gene, there were 17 cases in the experimental group (9 males and 8 females) and 19 cases in the control group (10 males and 9 females). The patients in the experimental group were treated with chest three-dimensional conformal radiotherapy (DT:50~60Gy,) combined with microwave hyperthermic therapy and enetinib hydrochloric acid (Camena), 125mg, oral, 3 times a day. The patients in the control group were treated with radiotherapy alone combined with microwave hyperthermia. The short-term efficacy and side effects of the two groups were compared. The efficacy was evaluated at 1, 3, 6 and 12 months after treatment. Results in the first month, the PR of the experimental group and the control group were 58.8% and 52.6%, respectively (蠂 ~ 2 鈮，

本文編號：2522756